How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients?

Cancer

Volumn 82, Issue 12, 1998, Pages 2449-2458

  Raad, Issam I ^a   Abi Said, Dima ^a   Rolston, Kenneth V ^a   Karl, Cynthia L ^b   Bodey, Gerald P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Box 47 ^*

Author keywords

Cancer; Fever; Imipenem; Neutropenia; Treatment

Indexed keywords

AMIKACIN; CILASTATIN PLUS IMIPENEM; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CANCER; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; FEVER; HOSPITAL COST; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SEIZURE; SUPERINFECTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CILASTATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HUMANS; IMIPENEM; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; THIENAMYCINS; TREATMENT OUTCOME;

EID: 0032526141     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980615)82:12<2449::AID-CNCR20>3.0.CO;2-O     Document Type: Article

References (25)

1. de Jongh CA, Joshi JH, Newman KA, Moody MR, Wharton R, Standiford HC, et al. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 1986;80(Suppl 5C):96-100.
2. Bodey GP, Elting L, Jones P, Avarez ME, Rolston K, Fainstein V. Imipenem/cilastatin therapy of infections in cancer patients. Cancer 1987;60:255-62.
3. Rolston KVI, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91.
4. Raad I, Whimbey E, Rolston K, Abi-Said D, Hachem R, Pandya R, et al. A comparison of imipenem to aztreonam with vancomycin as initial therapy for febrile neutropenic cancer patients. Cancer 1996;77:1386-94.
5. Bodey GP, Abi-Said D, Rolston KV, Raad I, Whimbey E. Imipenem versus cefoperazone-sulbactam both combined with vancomycin as therapy for fever in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 1996;15:625-34.
6. Bodey GP, Alvarez ME, Jones GP, Rolston KV, Steelhammer L, Fainstein V. Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother 1986; 30:211-4.
7. Liang R, Yung R, Chau PY, Chan TK, Lam WK, So SY, et al. Imipenem/cilastatin as initial therapy for febrile neutropenic patients. J Antimicrob Chemother 1988;22:765-70.
8. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Betalactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991;115:849-59.
9. Liang R, Yung R, Chiu E, Chau P-Y, Chan T-K, Lam W-K, et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother 1990;34:1336-41.
10. Freifeld AG, Walsh T, Marshall D, Gress J, Steinberg SM, Hathorn J, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-76.
11. Noorby SR, Vandercam BB, Louie T, Runde V, Norberg B, Anniko M, et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Scand J Infect Dis 1987;52:65-78.
12. Cornelissen JJ, de Graeff A, Verdonck F, Branger T, Rozenberg-Arska M, Verhoef J, et al. Imipenem versus gentamicin combined with either cefuroxime or cephalothin as initial therapy for febrile neutropenic patients. Antimicrob Agents Chemother 1992;36:801-7.
13. Leyland MJ, Bayston KF, Cohen J, Warren R, Newland AC, Bint AJ, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992;30:843-54.
14. Jones PG, Rolston KVI, Fainstein V, Elting L, Walters RS, Bodey GP. Aztreonam therapy in neutropenic patients with cancer. Am J Med 1986;81:243-8.
15. Winston DJ, McGrattan MA, Busuttil RW. Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections. Antimicrob Agents Chemother 1984;26:673-7.
16. Bulger RJ. In vitro effectiveness of kanamycin and kanamycin/cephalothin against Klebsiella: comparison with other antibiotics. Ann Intern Med 1967;523-32.
17. Lumish RM, Norden CW. Therapy of neutropenic rats infected with Pseudomonas aeruginosa. J Infect Dis 1976;133: 538-47.
18. McLaughlin FJ, Matthews WJ Jr., Strieder DJ, Sullivan B, Taneja A, Murphy P, et al. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis 1983; 147:559-67.
19. Gribble MJ, Chow AW, Naiman SC, Smith JA, Bowie WR, Sacks SL, et al. Prospective randomized trial of piperacillin monotherapy versus carboxipenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother 1983;24:388-93.
20. Shenep J, Hughes WT, Roberson PK, Blankenship KR, Baker DK Jr., Meyer WH, et al. Vancomycin, ticarcillin and amikacin compared with ticarcillin clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988;319:1053-8.
21. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-5.
22. The EORTC International Antimicrobial Therapy Cooperative Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-8.
23. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328: 1323-32.
24. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995;16:105-12.
25. Rolston KVI, Thirolf P, Ho DH, Bodey GP. Species dependent variability in the susceptibility of coagulase-negative staphylococci to various antimicrobial agents. J Antimicrob Chemother 1985;16:659-62.